Skip to content
Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.
Heitz F, Ataseven B, Staniczok C, Denkert C, Rhiem K, Hahnen E, Heikaus S, Moubarak M, Welz J, Dagres T, Vrentas V, Bommert M, Schneider S, Concin N, Harter P.
Cancers (Basel). 2023 Jan 29;15(3):818. doi: 10.3390/cancers15030818.
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
Chelariu-Raicu A, Trillsch F, Burges A, Czogalla B, Hester A, Wuerstlein R, Harbeck N, Mahner S.
Int J Gynecol Cancer. 2023 Jan 27:ijgc-2022-003990. doi: 10.1136/ijgc-2022-003990. Epub ahead of print.
Pairing tumor testing with germline sequencing increases the number of pathogenic germline variants identified. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Nefeli Dimopoulos C, Brierly K, Gibson J, Walther Z, Llor X.
Fam Cancer. [P-32: Research Categories» Gastric cancer-related syndromes.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Post navigation